@SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct

Dr Manasson presents on microbiome differences between monozygotic twins discordant for psoriatic disease. Differences seen in gut (Ruminococcus virtually absent in psoriatic) and scalp non-lesional skin microbiomes Abstr#0944 #ACR21 @RheumNow https://t.co/8Ch0M4dwUH

Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and retention rates: 🔷Improvement in BASDAI, PGA, global fnxn & depressive mood - similar in both ♂️&♀️ 🔷High SEC retention rates irrespective of gender @RheumNow #ACR21 abs909 https://t.co/rXa6ELXDJo

Dr Mahajan on lung disease in early RA. Common, airway disease in 60%, parenchymal disease in 30%. But minimal/no progression over 1 year which is reassuring. Abstr#574 #ACR21 @RheumNow https://t.co/s9r06MSStF

So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face. Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work! #ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM

Dr. P Crow #PhilipHenchLecture: from LE cell to IFN: LE cell definition: 👉substance in plasma 👉nuclear material from WBCs altered by the plasma factor 👉active phagocytic cells engulf the altered material #ACR21 @rheumnow https://t.co/jE9wnct6lP

Jorge Plutzky giving a cardiologist perspective at #ACR21. "We've gone from lower is better, to lowest is best" on LDL lowering. PCSK9 inhibitors have changed the game. @rheumnow https://t.co/oaBE99beSA

MUC5B and RA-ILD. Dr McDermott @jeffsparks show that MUC5B is associated with RA-ILD, older age at RA diagnosis, and ILD within 5 years of RA onset. Is this a different disease to other RA or modulation by the promotor variant? Abstr#0576 #ACR21 @RheumNow https://t.co/r2fQqxVY6N

Interesting study by @DrPoddubnyy et al. looking into the efficacy of SEC on HLAB27 subtypes (post hoc analysis of SKIPPAIN trial) ➡ SEC effective for both HLAB27+ and - grps ➡ Significant response seen among HLAB27+ and HLAB27 homozygous pts @RheumNow #ACR21 abs0917 https://t.co/St37kdGY65

And here is ORAL-Surveillance, small increase in MACE and malignancy with tofacitinib vs TNFi. 1 extra MACE per 319-567 patient years, 1 extra malignancy per 275 patient years. Abstr#0831 #ACR21 @RheumNow https://t.co/wMJnspTTBy